Effect of Livergol on the Improvement of Fatty Liver in Patients With Cancer Undergoing Irinotecan- and Oxaliplatin-Based Chemotherapy Regimen Publisher

Summary: Research shows Livergol improves fatty liver in cancer patients on chemo, enhancing liver health. #LiverHealth #CancerCare

Emami H¹ ; Shakeri A¹ ; Akhavan A¹ ; Shahbazigahrouei D² ; Akbari P¹
Source: Journal of Research in Medical Sciences Published:2018

Abstract

Background: The aim of this study was to determine the effect of Livergol on the improvement of fatty liver in patients with cancer undergoing irinotecan- and oxaliplatin-based chemotherapy regimen. Methods: This was an add-on nonrandomized clinical trial study on thirty selected eligible cancer patients undergoing irinotecan (8 patients) and oxaliplatin (22 patients) with diagnosed fatty liver disease-based liver ultrasonography, as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Patients in each group received Livergol at a dose of 140 mg daily for 1 month. ALT and AST levels as well as grade of fatty liver were evaluated before and after intervention. Results: In the oxaliplatin/Livergol group, 40% and 44.4% of patients who were in Grade 2 and 3 before intervention were altered to Grades 1 and 2, respectively (P = 0.005), and in irinotecan/Livergol group, the mentioned percentages were 80% and 66.7% (P = 0.014). The mean levels of ALT and AST enzymes were decreased in both groups after tacking Livergol; however, the observed decreases were not significantly different between groups. Conclusions: It was concluded that the adding of Livergol to oxaliplatin and irinotecan regimens significantly improved the fatty liver of patients and none of them was superior. © 2018 Journal of Research in Medical Sciences - Published by Wolters Kluwer - Medknow.